Evidence map›Paper›PMID 30212457›Full record

Trial reportPloS one2018

Exome sequencing-based identification of novel type 2 diabetes risk allele loci in the Qatari population.

Sarah L O'Beirne, Jacqueline Salit, Juan L Rodriguez-Flores, Michelle R Staudt, Charbel Abi Khalil, Khalid A Fakhro, Amal Robay, Monica D Ramstetter, Joel A Malek, Mahmoud Zirie and 11 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Frontiers in genetics · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

Sarah L O'BeirneDepartment of Genetic Medicine, Weill Cornell Medical College, New York, New York, United States of America.
Jacqueline SalitDepartment of Genetic Medicine, Weill Cornell Medical College, New York, New York, United States of America.
Juan L Rodriguez-FloresDepartment of Genetic Medicine, Weill Cornell Medical College, New York, New York, United States of America.
Michelle R StaudtDepartment of Genetic Medicine, Weill Cornell Medical College, New York, New York, United States of America.
Charbel Abi KhalilDepartment of Genetic Medicine, Weill Cornell Medical College-Qatar, Doha, Qatar.
Khalid A FakhroDepartment of Genetic Medicine, Weill Cornell Medical College-Qatar, Doha, Qatar.
Amal RobayDepartment of Genetic Medicine, Weill Cornell Medical College-Qatar, Doha, Qatar.
Monica D RamstetterDepartment of Genetic Medicine, Weill Cornell Medical College, New York, New York, United States of America.
Joel A MalekDepartment of Genetic Medicine, Weill Cornell Medical College-Qatar, Doha, Qatar.
Mahmoud ZirieDepartment of Medicine, Hamad Medical Corporation, Doha, Qatar.
Amin JayyousiDepartment of Medicine, Hamad Medical Corporation, Doha, Qatar.
Ramin BadiiLaboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar.
Ajayeb Al-Nabet Al-MarriLaboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar.
Abdulbari BenerDepartment of Medicine, Hamad Medical Corporation, Doha, Qatar.
Mai MahmoudDepartment of Medicine, Weill Cornell Medical College-Qatar, Doha, Qatar.
Maria J ChiuchioloDepartment of Genetic Medicine, Weill Cornell Medical College, New York, New York, United States of America.
Alya Al-ShakakiDepartment of Genetic Medicine, Weill Cornell Medical College-Qatar, Doha, Qatar.
Omar ChidiacDepartment of Genetic Medicine, Weill Cornell Medical College-Qatar, Doha, Qatar.
Dora StadlerDepartment of Medicine, Weill Cornell Medical College-Qatar, Doha, Qatar.
Jason G MezeyDepartment of Genetic Medicine, Weill Cornell Medical College, New York, New York, United States of America.
Ronald G CrystalDepartment of Genetic Medicine, Weill Cornell Medical College, New York, New York, United States of America.ORCID 0000-0001-6177-6839
Cornell University · USWeill Cornell Medical College in Qatar · QAHamad Medical Corporation · QASidra Medical and Research Center · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 2 diabetes (T2D) susceptibility is influenced by genetic and lifestyle factors. To date, the majority of genetic studies of T2D have been in populations of European and Asian descent. The focus of this study is on genetic variations underlying T2D in Qataris, a population with one of the highest incidences of T2D worldwide.

resultsIllumina HiSeq exome sequencing was performed on 864 Qatari subjects (574 T2D cases, 290 controls). Sequence kernel association test (SKAT) gene-based analysis identified an association for low frequency potentially deleterious variants in 6 genes. However, these findings were not replicated by SKAT analysis in an independent cohort of 12,699 exomes, primarly due to the absence of low frequency potentially deleterious variants in 5 of the 6 genes. Interestingly one of the genes identified, catenin beta 1 (CTNNB1, β-catenin), is the key effector of the Wnt pathway and interacts with the nuclear receptor transcription factor 7-like 2 (TCF7L2), variants which are the most strongly associated with risk of developing T2D worldwide. Single variant analysis did not identify any associated variants, suggesting the SKAT association signal was not driven by individual variants. None of the 6 associated genes were among 634 previously described T2D genes.

conclusionsThe observation that genes not previously linked to T2D in prior studies of European and Asian populations are associated with T2D in Qatar provides new insights into the complexity of T2D pathogenesis and emphasizes the importance of understudied populations when assessing genetic variation in the pathogenesis of common disorders.

Indexed as

AllelesExomebeta CateninDiabetes Mellitus, Type 2FemaleHigh-Throughput Nucleotide SequencingHumansMaleQatarRisk FactorsTranscription Factor 7-Like 2 ProteinWnt Signaling Pathwaybeta CateninCTNNB1 protein, humanTCF7L2 protein, humanTranscription Factor 7-Like 2 Protein

Identifiers

PMID30212457
PMCPMC6136697
OpenAlexW2892048508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.